1-5 of 5
Scott D. Lunin, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration

Michael R. Savona, MD, Hagop M. Kantarjian, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Katherine J. Walsh, MD, Raoul Tibes, MD PhD, Karen W.L. Yee, MD, Wendy Stock, MD, Elizabeth A. Griffiths, MD, Elias Jabbour, MD, Scott D. Lunin, MD, Todd L. Rosenblat, MD MS, Nikolai A. Podoltsev, MD PhD, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2957.
https://doi.org/10.1182/blood-2019-129962
Published: 2019
Journal Articles

Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients

Elizabeth A. Griffiths, MD, Hagop M. Kantarjian, MD, Casey L. O'Connell, MD, Karen W.L. Yee, MD, Wendy Stock, MD, Naval G. Daver, MD, Elias Jabbour, MD, Ellen K. Ritchie, MD, Jean-Pierre Issa, MD, Katherine J. Walsh, MD, David A. Rizzieri, MD, Scott D. Lunin, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Gail J. Roboz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1319.
https://doi.org/10.1182/blood-2019-131394
Published: 2019
Journal Articles

Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Guillermo Garcia-Manero, MD, Ellen K. Ritchie, MD, Katherine J. Walsh, MD, Michael R. Savona, MD, Hagop M. Kantarjian, MD, Patricia L. Kropf, MD, Casey L. O'Connell, MD, Raoul Tibes, MD PhD, Naval G. Daver, MD, Elias J. Jabbour, MD, Scott D. Lunin, MD, Todd L. Rosenblat, MD MS, Karen W.L. Yee, MD, Wendy Stock, MD, Elizabeth A. Griffiths, MD, Joseph Mace, MD, Nikolai A. Podoltsev, MD PhD, Jesus G. Berdeja, MD, Jean-Pierre Issa, MD, Sue Naim, Yong Hao, MD, Mohammad Azab, MD, Gail J. Roboz, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 231.
https://doi.org/10.1182/blood-2018-99-110465
Published: 2018
Journal Articles

Results from the Phase 3 DUO TM Trial: A Randomized Comparison of Duvelisib Vs Ofatumumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Ian W. Flinn, MD PhD, Peter Hillmen, MBChB, PhD, Marco Montillo, MD, Zsolt Nagy, MD PhD, Árpád Illés, MD PhD, Gabriel Etienne, MD PhD, Julio Delgado, MD, Bryone Jean Kuss, PhDBMBS,FRCPA,FRACP, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Zoltán Gasztonyi, MD, Fritz Offner, MD, Scott D Lunin, MD, Francesco Bosch, MD, Matthew S. Davids, MD MMSc, Nicole Lamanna, MD, Ulrich Jaeger, MD, Paolo Ghia, Florence Cymbalista, MD, Craig A. Portell, MD, Alan P Skarbnik, MD, Amanda Cashen, MD, Virginia Kelly, MD, Barry Turnbull, PhD, Stephan Stilgenbauer, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 493.
https://doi.org/10.1182/blood.V130.Suppl_1.493.493
Published: 2017
Journal Articles

Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma

Ian W. Flinn, MD PhD, Carole B. Miller, MD, Kirit M Ardeshna, Scott Tetreault, MD, Sarit E. Assouline, MD MSc, Pier Luigi Zinzani, MD PhD, Jiri Mayer, MD, Michele Merli, MD, Scott D Lunin, MD, Andrew R. Pettitt, Zsolt Nagy, MD PhD, Oliver Tournilhac, MD, Karim Etienne Abou-Nassar, MD, Michael Crump, MD, Eric D. Jacobsen, MD, Sven de Vos, MD PhD, Pedro Santabarbara, MD, Weiliang Shi, PhD, Lori Steelman, MA, Nina D. Wagner-Johnston, MD
Journal: Blood
Blood (2016) 128 (22): 1218.
https://doi.org/10.1182/blood.V128.22.1218.1218
Published: 2016